ENANTA PHARMACEUTICALS, INC Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ENANTA PHARMACEUTICALS, INC (ENTA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-12
- ENANTA PHARMACEUTICALS, INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $1.20M, a 95.00% decline from fiscal 2024.
- ENANTA PHARMACEUTICALS, INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $23.96M, a 527.72% increase from fiscal 2023.
- ENANTA PHARMACEUTICALS, INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $3.82M, a 84.04% decline from fiscal 2022.
- ENANTA PHARMACEUTICALS, INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $23.91M, a 620.18% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 3 quarters · filed 2026-05-13 | $98.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 10-Q · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $98.00K derived: sum of 3 quarters · filed 2026-08-12 | $652.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | $98.00K derived: sum of 2 quarters · filed 2026-08-12 | $652.00K derived: sum of 3 quarters · filed 2026-08-12 | $1.20M 10-K · filed 2025-11-19 |
| 2025-06-30 | $98.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12 | $652.00K derived: sum of 2 quarters · filed 2026-08-12 | $1.20M 10-Q · filed 2026-08-12 | $2.18M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $554.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | $1.10M 10-Q · filed 2026-05-13 | $2.09M derived: sum of 3 quarters · filed 2026-05-13 | $2.44M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $547.00K 10-Q · filed 2026-02-11 | $1.53M derived: sum of 2 quarters · filed 2026-02-11 | $1.89M derived: sum of 3 quarters · filed 2026-02-11 | $24.51M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-09-30 | $985.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | $1.34M derived: sum of 2 quarters · filed 2025-11-19 | $23.96M derived: sum of 3 quarters · filed 2025-11-19 | $23.96M 10-K · filed 2025-11-19 |
| 2024-06-30 | $358.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-13 | $22.98M derived: sum of 2 quarters · filed 2025-08-13 | $22.98M 10-Q · filed 2025-08-13 | $23.21M derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-03-31 | $22.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14 | $22.62M 10-Q · filed 2025-05-14 | $22.85M derived: sum of 3 quarters · filed 2025-11-19 | $23.56M derived: sum of 4 quarters · filed 2025-11-19 |
| 2023-12-31 | $0.00 10-Q · filed 2025-02-12 | $237.00K derived: sum of 2 quarters · filed 2025-11-19 | $947.00K derived: sum of 3 quarters · filed 2025-11-19 | $3.02M derived: sum of 4 quarters · filed 2025-11-19 |
| 2023-09-30 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | $947.00K derived: sum of 2 quarters · filed 2025-11-19 | $3.02M derived: sum of 3 quarters · filed 2025-11-19 | $3.82M 10-K · filed 2025-11-19 |
| 2023-06-30 | $710.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-07 | $2.78M derived: sum of 2 quarters · filed 2024-08-07 | $3.58M 10-Q · filed 2024-08-07 | $4.51M derived: sum of 4 quarters · filed 2024-11-27 |
| 2023-03-31 | $2.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-08 | $2.87M 10-Q · filed 2024-05-08 | $3.80M derived: sum of 3 quarters · filed 2024-11-27 | $11.22M derived: sum of 4 quarters · filed 2024-11-27 |
| 2022-12-31 | $799.00K 10-Q · filed 2024-02-08 | $1.73M derived: sum of 2 quarters · filed 2024-11-27 | $9.15M derived: sum of 3 quarters · filed 2024-11-27 | $9.15M derived: sum of 4 quarters · filed 2024-11-27 |
| 2022-09-30 | $926.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-27 | $8.35M derived: sum of 2 quarters · filed 2024-11-27 | $8.35M derived: sum of 3 quarters · filed 2024-11-27 | $23.91M 10-K · filed 2024-11-27 |
| 2022-06-30 | $7.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-08 | $7.42M derived: sum of 2 quarters · filed 2023-08-08 | $22.98M 10-Q · filed 2023-08-08 | $23.25M derived: sum of 4 quarters · filed 2023-11-22 |
| 2022-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-09 | $15.56M 10-Q · filed 2023-05-09 | $15.82M derived: sum of 3 quarters · filed 2023-11-22 | $16.36M derived: sum of 4 quarters · filed 2023-11-22 |
| 2021-12-31 | $15.56M 10-Q · filed 2023-02-08 | $15.82M derived: sum of 2 quarters · filed 2023-11-22 | $16.36M derived: sum of 3 quarters · filed 2023-11-22 | $16.97M derived: sum of 4 quarters · filed 2023-11-22 |
| 2021-09-30 | $263.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-22 | $803.00K derived: sum of 2 quarters · filed 2023-11-22 | $1.41M derived: sum of 3 quarters · filed 2023-11-22 | $3.32M 10-K · filed 2023-11-22 |
| 2021-06-30 | $540.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-08 | $1.15M derived: sum of 2 quarters · filed 2022-08-08 | $3.06M 10-Q · filed 2022-08-08 | $3.43M derived: sum of 4 quarters · filed 2022-11-23 |
| 2021-03-31 | $610.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-09 | $2.52M 10-Q · filed 2022-05-09 | $2.89M derived: sum of 3 quarters · filed 2022-11-23 | $3.57M derived: sum of 4 quarters · filed 2022-11-23 |
| 2020-12-31 | $1.91M 10-Q · filed 2022-02-10 | $2.28M derived: sum of 2 quarters · filed 2022-11-23 | $2.96M derived: sum of 3 quarters · filed 2022-11-23 | $3.83M derived: sum of 4 quarters · filed 2022-11-23 |
| 2020-09-30 | $377.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-23 | $1.06M derived: sum of 2 quarters · filed 2022-11-23 | $1.92M derived: sum of 3 quarters · filed 2022-11-23 | $3.05M 10-K · filed 2022-11-23 |
| 2020-06-30 | $679.00K 10-Q · filed 2020-08-10 | $1.54M derived: sum of 2 quarters · filed 2020-08-10 | $2.68M 10-Q · filed 2021-08-09 | |
| 2020-03-31 | $866.00K 10-Q · filed 2020-05-11 | $2.00M 10-Q · filed 2021-05-10 | ||
| 2019-12-31 | $1.13M 10-Q · filed 2021-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |